Jasper Therapeutics says about 68.94% of its warrants were bought back, costing over $2.7 million.

Nov 10, 2026, 11:05 AM ETPayoutRead the original at globenewswire.com

Neutral

Jasper expects to spend about $2.8 million to buy warrants covering 69% of those outstanding. Fewer warrants may limit future share issuance, but the cash cost means this alone does not clearly change its outlook.

JSPR · Jasper Therapeutics, Inc.

AI read · Neutral

The AI's read

Buying back most of these warrants may limit future share issuance, but Jasper must spend company cash to do it. The source does not say how many shares the warrants could have created, so the benefit cannot be weighed against the cash cost.

Get alerts for JSPR

Follow Jasper Therapeutics, Inc. (JSPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JSPR

Free on the App Store and Google Play, or on the web.